Neoadjuvant Chemotherapy Combined With Targeted Treatment in High-risk Retroperitoneal Sarcoma

NCT05844813 · clinicaltrials.gov ↗

PHASE4

Phase

ENROLLING_BY_INVITATION

Status

102

Enrollment

OTHER

Sponsor class

Conditions

Retroperitoneal Sarcoma

Interventions

DRUG: Doxorubicin+Ifosfamide+Anlotinib(AI+A)
PROCEDURE: Radical Surgery

Sponsor

Peking University International Hospital

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]